{"id":"a333366d-859c-58ab-aa7c-4a9f55fc1cd3","stable_key":"1acdb1e8-2159-5c7f-b39f-0153ff8024ae:taurine-leukemia-venetoclax","predicate":"inhibition_sensitizes","statement":"TAUT inhibition combined with venetoclax synergistically reduced growth of primary human AML cells in the reported experiments.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"c44e591c-1637-5792-9537-6ae7cf4a4c2b","mechanism_event_label":"Blocking nutrient uptake affected response to an anticancer drug in patient-derived cells.","subject":{"id":"c00b89ac-1c32-5d7d-aec4-490af879460a","slug":"slc6a6","display_name":"Human taurine transporter / SLC6A6","entity_type_key":"protein"},"object":{"id":"f8adffc0-6d6e-553b-83d5-a0db5ae8c9e2","slug":"human-taurine-aml-growth","display_name":"Patient-derived human AML cell growth in taurine experiments","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c44e591c-1637-5792-9537-6ae7cf4a4c2b","stable_key":"1acdb1e8-2159-5c7f-b39f-0153ff8024ae:taurine-leukemia-venetoclax-event","event_type":"observed_relationship","label":"Blocking nutrient uptake affected response to an anticancer drug in patient-derived cells.","description":"TAUT inhibition combined with venetoclax synergistically reduced growth of primary human AML cells in the reported experiments.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c00b89ac-1c32-5d7d-aec4-490af879460a","slug":"slc6a6","display_name":"Human taurine transporter / SLC6A6","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f8adffc0-6d6e-553b-83d5-a0db5ae8c9e2","slug":"human-taurine-aml-growth","display_name":"Patient-derived human AML cell growth in taurine experiments","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c83301e5-a2e9-5c96-bb55-ce7e33549186","slug":"venetoclax","display_name":"Venetoclax","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"e423cd36-f183-522b-a5e4-5f9ef50eee7e","slug":"taurine","display_name":"Taurine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Ex-vivo human AML; venetoclax-resistance expression analyses.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Measured experimental combination effect, not a proven clinical interaction between taurine supplements and venetoclax.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Taurine collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"taurine","display_name":"Taurine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Blocking nutrient uptake affected response to an anticancer drug in patient-derived cells.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Taurine from tumour niche drives glycolysis to promote leukaemogenesis. · 2025 · https://pubmed.ncbi.nlm.nih.gov/40369079/ · DOI 10.1038/s41586-025-09018-7","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"aa376356-ecbf-5771-9c10-040568a51154","evidence_kind":"source_excerpt","locator":"Lines 561-567","start_line":561,"end_line":567,"excerpt":"## taurine-leukemia-venetoclax\nBlocking nutrient uptake affected response to an anticancer drug in patient-derived cells.\nTAUT inhibition combined with venetoclax synergistically reduced growth of primary human AML cells in the reported experiments.\nModel: Ex-vivo human AML; venetoclax-resistance expression analyses.\nLimitations: Measured experimental combination effect, not a proven clinical interaction between taurine supplements and venetoclax.\nEvidence access: Primary abstract\nTaurine from tumour niche drives glycolysis to promote leukaemogenesis. · 2025 · https://pubmed.ncbi.nlm.nih.gov/40369079/ · DOI 10.1038/s41586-025-09018-7","model_system":"Ex-vivo human AML; venetoclax-resistance expression analyses.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dc8d9ab8-fdf9-5107-877c-336cf8005097","stable_key":"import-1acdb1e8-2159-5c7f-b39f-0153ff8024ae","title":"Taurine: synthesis, transport, mitochondrial decoding and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"c6cb77619a374d9b1b04830032fdd3b33d269d160df5baba3778fad5adf57db5","revision_id":"cc45c491-cc6a-5426-ab72-d7c6d26c3614","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}